MCC patient samples heterogeneously expressed B-cell and neuroendocrine markers and novel molecular targets including BCMA, CD10, CD93, PAX5, TdT, IgA, and CD19. This evidence concerns the gene TNFRSF17 and Merkel cell skin cancer.